C11orf1 Inhibitors
C11orf1 inhibitors, as hypothesized, encompass a range of compounds that could interfere with the functional activity of C11orf1. Staurosporine, being a broad kinase inhibitor, could prevent the phosphorylation that is potentially necessary for the activation or stabilization of C11orf1. Similarly, the inhibition of protein synthesis by cycloheximide could decrease the levels of proteins that interact with or are necessary for the function of C11orf1. Compounds like rapamycin and Brefeldin A could disrupt processes essential for the activity of C11orf1 by inhibiting pathways crucial for protein synthesis and trafficking, respectively.
Inhibitors like PD98059, SP600125, SB203580, and U0126 target specific components of the MAPK signaling cascade, such as MEK, JNK, and p38 MAPK. This implies that if C11orf1 is part of or is regulated by the MAPK pathway, these inhibitors could decrease its activity. Furthermore, proteasome inhibitors such as MG132 and Bortezomib could lead to protein accumulation and cellular stress, which might impede C11orf1's activity if it is subject to regulation by proteostatic mechanisms. Thapsigargin's role in disrupting calcium homeostasis could suggest that C11orf1 is sensitive to calcium signaling, whereas 2-Deoxy-D-glucose could reduce the energy supply necessary for C11orf1's functional activity. Lastly, Cyclosporin A might modulate C11orf1 activity by affecting dephosphorylation processes through the inhibition of calcineurin.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit a wide range of kinases potentially involved in the activation or stabilization of C11orf1. If C11orf1 is regulated by phosphorylation, staurosporine could lead to its functional inhibition. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis, which could decrease the synthesis of proteins required for C11orf1 function or proteins interacting with C11orf1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can downregulate protein synthesis and autophagy processes. If C11orf1 function is linked with proteins synthesized via mTOR pathways or autophagy, rapamycin could inhibit its activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts protein transport by blocking the function of the Golgi apparatus. If C11orf1 is a protein that requires proper localization through the Golgi, Brefeldin A could inhibit its functional activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A glucose analog that inhibits glycolysis by inhibiting hexokinase. If C11orf1 is involved in pathways that are energy-dependent, this could indirectly inhibit its activity by reducing available ATP. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
An inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels. If C11orf1 is regulated by calcium signaling, thapsigargin could disrupt its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. If C11orf1 is downstream of or regulated by the MAPK pathway, U0126 could lead to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that would impede the PI3K/Akt signaling pathway. If C11orf1 function is dependent on this pathway for activation or stabilization, LY294002 could inhibit its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor with a slightly different mechanism than U0126. If C11orf1 is involved in the MAPK pathway, PD98059 could also lead to its functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can increase the levels of ubiquitinated proteins. If C11orf1 is degraded by the proteasome, MG132 could theoretically lead to its functional inhibition by accumulation of misfolded proteins. | ||||||